Home > Boards > US Listed > Biotechs > Vascular Biogenics Ltd. (VBLT)

I was happy to hear they plan to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Oren1976 Member Profile
 
Followed By 2
Posts 381
Boards Moderated 0
Alias Born 12/04/16
160x600 placeholder
VET, TCOM, TTM and ZI among premarket gainers Seeking Alpha - 2/23/2021 8:18:53 AM
VBL Therapeutics gets green light for VB-111 study in ovarian cancer, shares up 16% Seeking Alpha - 2/22/2021 7:32:38 AM
VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Ena... GlobeNewswire Inc. - 2/22/2021 7:00:00 AM
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients GlobeNewswire Inc. - 1/27/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/15/2021 7:05:09 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/15/2021 7:03:58 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/11/2021 6:02:46 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 12/30/2020 4:17:39 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/24/2020 4:51:30 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/16/2020 7:18:35 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2020 7:03:18 AM
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16 GlobeNewswire Inc. - 11/2/2020 7:00:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/29/2020 9:01:19 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/19/2020 4:10:50 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/13/2020 8:31:06 AM
VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conferenc... GlobeNewswire Inc. - 9/15/2020 8:00:10 AM
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple ... GlobeNewswire Inc. - 9/11/2020 8:00:10 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/26/2020 5:21:36 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/13/2020 7:01:01 AM
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 8/13/2020 7:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/12/2020 8:46:07 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/5/2020 4:33:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/3/2020 8:39:54 AM
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13 GlobeNewswire Inc. - 8/3/2020 8:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/31/2020 6:29:30 AM
Oren1976   Wednesday, 11/28/18 08:33:24 PM
Re: None
Post # of 2011 
I was happy to hear they plan to try vb-111 without avastin in GBM and more but I was very disappointed to hear they allow avastin after progression in gbm. I believe it's a huge mistake to add avastin at anytime. Sometimes doctors think it's a progression and it's not and also avastin destroy the immune response. Brain implant won't hurt these guys at VBL as if they didn't each enough shit from the devil avastin

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences